Publications by authors named "Steven Bellon"

Claim this Profile
D
Discovery of FHD-286, a First-in-Class, Orally Bioavailable, Allosteric Dual Inhibitor of the Brahma Homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase Activity for the Treatment of SWItch/Sucrose Non-Fermentable (SWI/SNF) Dependent Cancers.
Rishi G Vaswani, David S Huang, Neville Anthony, Lan Xu, Richard Centore, Steven F Bellon

J Med Chem· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1.
Alexander M Taylor, Chris Bailey, Lisa D Belmont, Robert Campbell, Nico Cantone, Steven F Bellon

J Med Chem· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors.
Victor S Gehling, John P McGrath, Martin Duplessis, Avinash Khanna, Francois Brucelle, Steven F Bellon

ACS Med Chem Lett· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300.
Terry D Crawford, F Anthony Romero, Kwong Wah Lai, Vickie Tsui, Alexander M Taylor, Steven Bellon

J Med Chem· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas.
Rishi G Vaswani, Victor S Gehling, Les A Dakin, Andrew S Cook, Christopher G Nasveschuk, Steven F Bellon

J Med Chem· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of potent, selective KDM5 inhibitors.
Victor S Gehling, Steven F Bellon, Jean-Christophe Harmange, Yves LeBlanc, Florence Poy

Bioorg Med Chem Lett· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
S-adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3.
Hariharan Jayaram, Dominik Hoelper, Siddhant U Jain, Nico Cantone, Stefan M Lundgren, Steven Bellon

Proc Natl Acad Sci U S A· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.
Alessandro A Boezio, Katrina W Copeland, Karen Rex, Brian K Albrecht, David Bauer, Steven F Bellon

J Med Chem· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to Discovery of Potent and Selective 8-Fluorotriazolopyridine c-Met Inhibitors.
Emily A Peterson, Yohannes Teffera, Brian K Albrecht, David Bauer, Steven F Bellon

J Med Chem· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors.
Emily A Peterson, Yohannes Teffera, Brian K Albrecht, David Bauer, Steven F Bellon

J Med Chem· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 1H-pyrazol-3(2H)-ones as potent and selective inhibitors of protein kinase R-like endoplasmic reticulum kinase (PERK).
Adrian L Smith, Kristin L Andrews, Holger Beckmann, Steven F Bellon, Pedro J Beltran

J Med Chem· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.
Christiane M Bode, Alessandro A Boezio, Brian K Albrecht, Steven F Bellon, Loren Berry

Bioorg Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.
Longbin Liu, Mark H Norman, Matthew Lee, Ning Xi, Aaron Siegmund, Steven F Bellon

J Med Chem· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives.
Mark H Norman, Longbin Liu, Matthew Lee, Ning Xi, Ingrid Fellows, Steven F Bellon

J Med Chem· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor.
John P Duffy, Edmund M Harrington, Francesco G Salituro, John E Cochran, Jeremy Green, Steven F Bellon

ACS Med Chem Lett· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.
Alessandro A Boezio, Loren Berry, Brian K Albrecht, David Bauer, Steven F Bellon

Bioorg Med Chem Lett· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer.
Isabelle Dussault, Steven F Bellon

Anticancer Agents Med Chem· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and biological evaluation of potent c-Met inhibitors.
Noel D D'Angelo, Steven F Bellon, Shon K Booker, Yuan Cheng, Angela Coxon

J Med Chem· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458).
Longbin Liu, Aaron Siegmund, Ning Xi, Paula Kaplan-Lefko, Karen Rex, Steven F Bellon

J Med Chem· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
c-Met inhibitors with different binding modes: two is better than one.
Isabelle Dussault, Steven F Bellon

Cell Cycle· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.
Brian K Albrecht, Jean-Christophe Harmange, David Bauer, Loren Berry, Christiane Bode, Steven F Bellon

J Med Chem· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.
Steven F Bellon, Paula Kaplan-Lefko, Yajing Yang, Yihong Zhang, Jodi Moriguchi

J Biol Chem· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The structure of dimeric ROCK I reveals the mechanism for ligand selectivity.
Marc Jacobs, Koto Hayakawa, Lora Swenson, Steven Bellon, Mark Fleming

J Biol Chem· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase.
Steven Bellon, Jonathan D Parsons, Yunyi Wei, Koto Hayakawa, Lora L Swenson

Antimicrob Agents Chemother· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Active-site residues of Escherichia coli DNA gyrase required in coupling ATP hydrolysis to DNA supercoiling and amino acid substitutions leading to novobiocin resistance.
Christian H Gross, Jonathan D Parsons, Trudy H Grossman, Paul S Charifson, Steven Bellon

Antimicrob Agents Chemother· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis